While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
The firm also recently released the results of collaborations with Admera Health and RareCyte that used its multiplex PCR-based target enrichment technology.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
Emerging from stealth mode, the Toronto-based firm will use the platform to identify circulating tumor cells and spur drug development in the lung cancer space.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.
